



ProSight invented a transformative modality enabling clinicians to visualize the most precise prostate cancer biomarker known to science in real-time, during the biopsy, overlaid on current images, allowing on-the-fly biopsy adjustments, for harvesting the most relevant samples, maximizing detection rate and the accuracy of discriminating clinically significant cancer.

Testimonials

"ProSight can assist in sampling the correct region of the prostate, leading to more representative tissue being harvested... complements and adds value to MRI..." "ProSight has found a reliable, independent, direct marker for prostate cancer, to improve the sensitivity of prostate biopsy procedures and provide real-time pre-diagnosis for urologists during the biopsy itself."

Prof. M. Emberton - Dean, Fac. Med-Sci. Univ. College London

Prof. N. Rofsky - former Chairman, Dpt. of Radiology - Southwestern MC, Dallas

Prof. R. Lenkinski - Mount Sinai Group, NY.

Bridge Round

\$300-600K, 6-9 months - via SAFE - in prep. for series A (\$8M + \$4M in grants)

Management Team

Avi Simon - CEO, co-Founder
Dr. M. Weksler - CTO, co-Founder
Einat Zisman, Ph.D., MBA VP BD
Prof. Ilan Leibovitch, MD - CMO
Prof. Robert Lenkinski - MRI PCA Expert
John Smith, M.D., J.D. - Regulatory Counsel, Hogan Lovells



Contact

Avi Simon:
+972-54-484-3220
avi@prosight.site

Einat Zisman:
+972-50-517-2233
einat@prosight.site



BIOMARKER - GUIDED BIOPSY

The Next Standard of Care in Prostate Cancer Diagnosis

What We Do

ProSight is pioneering a transformative modality in prostate cancer diagnosis, providing real-time, biomarker-based guidance to revolutionize the detection and characterization of tumors. Based on strong IP, a proven team, and excellent clinical proof of concept.

ProSight is poised to set the new standard in a \$10B+ market, enabling precision diagnostics for all patients.

Need and Opportunity

Diagnostic Inaccuracy

MRI-guided biopsies: 50% false positive rate
Ultrasound biopsies: 30% false negative rate

No real-time feedback

Missed tumors and false negatives lead to repeat invasive biopsies and delayed detection

Expert Dependency

Current methods heavily rely on specialist expertise for MRI region of interest definition

Patient Impact

Anxiety, discomfort, delayed treatment, over/under treatment, 2nd leading cause of cancer death in US men

Economic Burden

Metastatic patient care costs 50x higher than non-metastatic care cost - earlier detection is essential

Clinical Uncertainty

Difficulty differentiating between clinically significant cancer grades affects treatment decisions and outcomes

Industry Consensus: independent biomarkers are essential for a significant leap

Our Solution: Real-time Biomarker-Guided Biopsy

- Proprietary software detects **zinc depletion** - the most reliable biomarker for prostate cancer
- Real-time analysis** during biopsy procedure using adapted off-the-shelf XRF for scanning
- Results **overlaid on current imaging**, allowing on-the-fly guidance to suspicious regions
- Seamless integration** into existing workflow
- Maximizes diagnostic accuracy** and likelihood of finding all tumors in the first biopsy
- Decisive, tailored **treatment decisions**
- Reduces missed tumors & unnecessary procedures - **saving \$Bn's**, while improving patient outcomes

Performance Metrics Clinical Study

Specificity	Accuracy
98%	97%
Sensitivity	Prostatitis IDed
94%	100%

Competitive Landscape

Biopsy Approach	Real-Time Feedback	High Accuracy	Overlay on MRI/US	Non-Destruct	Major Player
US-Based	×	×	✓	✓	Commodity
MRI-Guided	×	⦿	✓	✓	Siemens
Mini-MRI	×	⦿	✓	✓	Promaxo
Micro-US	×	⦿	✓	✓	Exact Imaging
Biomarker-Guided	✓	✓	✓	✓	ProSight

Product Roadmap and Milestones

Today	6 Months	12 Months	18 Months	24 Months	27 Months	36+ Months
Bridge Round \$300-600K SAFE	* Series A \$8M + \$4M Grants	FDA 510(k) Submission	Series B \$20M	ProSight 1.0 Start of Sales	ProSight 2.0 Full System Launch	Expansion Additional Markets